Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Cash from Operations data on file, last reported at 73279000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 70.26% year-over-year to 73279000.0 in Q1 2026; TTM through Mar 2026 was 268781000.0, a 726.36% increase from a year earlier, with the FY2025 full-year figure at 238541000.0, up 2167.98% from the prior year.
• Cash from Operations for Q1 2026 stood at 73279000.0, up from 6064000.0 in the prior quarter.
• Over the last five years, Cash from Operations for TBPH reached as high as 208074000.0 in Q2 2025 and fell as low as 26069000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 15933117.65 across 5 years, with a median of 4415000.0 in 2024.
• On a YoY basis, Cash from Operations climbed as much as 4812.89% in 2025 and fell as far as 572.28% in 2025.
• Year by year, Cash from Operations stood at 54913000.0 in 2022, then tumbled by 101.56% to 854000.0 in 2023, then decreased by 5.62% to 902000.0 in 2024, then plunged by 572.28% to 6064000.0 in 2025, then surged by 1308.43% to 73279000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 73279000.0 in Q1 2026, 6064000.0 in Q4 2025, and 6508000.0 in Q3 2025.